Combination Chemotherapy with Vinblastine, Ifosfamide and Cisplatin in Bulky Seminoma

Authors

  • C. Clemm Department of Internal Medicine III, Klinikum Grosshadern of the University of Munich, D-8000 Munich 70, West Germany
  • R. Hartenstein Department of Internal Medicine III, Klinikum Grosshadern of the University of Munich, D-8000 Munich 70, West Germany
  • N. Willich Department of Internal Medicine III, Klinikum Grosshadern of the University of Munich, D-8000 Munich 70, West Germany
  • G. Ledderose Department of Internal Medicine III, Klinikum Grosshadern of the University of Munich, D-8000 Munich 70, West Germany
  • W. Wilmanns Department of Internal Medicine III, Klinikum Grosshadern of the University of Munich, D-8000 Munich 70, West Germany

DOI:

https://doi.org/10.3109/02841868909111253

Keywords:

Seminoma, bulky, cisplatin, vinblastine, ifosfa- mide, treatment results

Abstract

Since 1982, 24 patients with bulky seminoma were treated with the VIP-regimen consisting of vinblastine 6 mg/m2 days 1+2, ifosfamide 1.5 g/m2 days 1-5, cisplatin 20 mg/m2 days 1-5. One patient showed primary progression, another patient partial remission, and one patient died during the first cycle. All the other patients had complete remission (21/24=87%), which was documented histologically in 9 patients. One patient relapsed but obtained complete remission after repeated treatment. Thus 21 patients are currently living without disease after a median observation time of 30+ months. Bone marrow toxicity was severe, leading to dose reduction in more than 50% of the patients. No other severe side effects were observed. We conclude that the regimen is highly effective in bulky seminoma. Reduction of the vinblastine dose is recommended because of bone marrow toxicity.

Downloads

Download data is not yet available.

Downloads

Published

1989-01-01

How to Cite

Clemm, C., Hartenstein, R., Willich, N., Ledderose, G., & Wilmanns, W. (1989). Combination Chemotherapy with Vinblastine, Ifosfamide and Cisplatin in Bulky Seminoma. Acta Oncologica, 28(2), 231–235. https://doi.org/10.3109/02841868909111253